Immunotherapeutic properties of chemotherapy

Current Opinion in Pharmacology

Volumn 35, Issue , 2017, Pages 83-88

  Fournier, Carole ^a,b   Rivera Vargas, Thaiz ^a,b   Martin, Tiffany ^a,b   Melis, Andréa ^a,b   Apetoh, Lionel ^a,b,c  

^a Institut Médical de Génétique et d Immunologie   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BARNESIELLA INTESTINIHOMINIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; ENTEROCOCCUS HIRAE; GASTROINTESTINAL STROMAL TUMOR; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOMODULATION; IMMUNOPOTENTIATION; INTESTINE FLORA; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 85019555841     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.05.003     Document Type: Review

References (55)

1. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
2. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
3. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (80-.) 331 (2011), 1565–1570.
4. Hersh, E.M., Oppenheim, J., Inhibition of in vitro lymphocyte transformation chemotherapy in Man1. Cancer Res. 27 (1967), 98–105.
5. Schwartz, H.S., Grindey, G.B., Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 33 (1973), 1837–1844.
6. Bracci, L., Schiavoni, G., Sistigu, A., Belardelli, F., Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21 (2014), 15–25.
7. Chow, J., Franz, K.M., Kagan, J.C., PRRs are watching you: localization of innate sensing and signaling regulators. Virology 479:480 (2015), 104–109.
8. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007), 54–61.
9. Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., Špíšek, R., Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 71 (2011), 4821–4833.
10. Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M.T., Belardelli, F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71 (2011), 768–778.
11. Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D.E., et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521 (2015), 94–98.
12. Cirone, M., Di Renzo, L., Lotti, L.V., Conte, V., Trivedi, P., Santarelli, R., Gonnella, R., Frati, L., Faggioni, A., Primary effusion lymphoma cell death induced by Bortezomib and AG 490 activates dendritic cells through CD91. PLoS One, 2012, 7.
13. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007), 1050–1059.
14. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15 (2009), 1170–1178.
15. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remédios, C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20 (2014), 1301–1309.
16. Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura a Tajeddine, N., et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30 (2011), 1147–1158.
17. Vacchelli, E., Ma, Y., Baracco, E.E., Sistigu, A., Enot, D.P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science (80-.) 350 (2015), 972–978 This study reveals, by identifying candidate genetic defects in cancer patients treated with chemotherapy, the importance of FRP1 signaling in chemotherapy-induced anticancer immune responses.
18. Colangelo, T., Polcaro, G., Ziccardi, P., Muccillo, L., Galgani, M., Pucci, B., Rita Milone, M., Budillon, A., Santopaolo, M., Mazzoccoli, G., et al. The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells. Cell. Death Dis., 7, 2016, e2108.
19. Yang, H., Ma, Y., Chen, G., Zhou, H., Yamazaki, T., Klein, C., Pietrocola, F., Vacchelli, E., Souquere, S., Sauvat, A., et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology, 5, 2016, e1149673.
20. Lutsiak, M.E.C., Semnani, R.T., De Pascalis, R., Kashmiri, S.V.S., Schlom, J., Sabzevari, H., Inhibition of CD4 + 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105 (2005), 2862–2868.
21. Ghiringhelli, F., Menard, C., Puig, P.E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., Chauffert, B., Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 (2007), 641–648.
22. Madondo, M.T., Quinn, M., Plebanski, M., Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat. Rev. 42 (2016), 3–9.
23. Loyher, P.L., Rochefort, J., Baudesson De Chanville, C., Hamon, P., Lescaille, G., Bertolus, C., Guillot-Delost, M., Krummel, M.F., Lemoine, F.M., Combadière, C., et al. CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity. Cancer Res. 76 (2016), 6483–6494.
24. Suzuki, E., Kapoor, V., Jassar, A.S., Kaiser, L.R., Albelda, S.M., Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11 (2005), 6713–6721.
25. Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé C., G. hiringhelli F: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70 (2010), 3052–3061.
26. Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G.V., Shurin, M.R., Umansky, V., Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190 (2013), 2464–2471.
27. Kanterman, J., Sade-Feldman, M., Biton, M., Ish-Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., Baniyash, M., Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 74 (2014), 6022–6035.
28. Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73 (2013), 3499–3510.
29. Iriyama, N., Fujisawa, S., Yoshida, C., Wakita, H., Chiba, S., Okamoto, S., Kawakami, K., Takezako, N., Kumagai, T., Inokuchi, K., et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am. J. Hematol. 90 (2015), 819–824.
30. Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114 (2004), 379–388.
31. Lowe, D.B., Bose, A., Taylor, J.L., Tawbi, H., Lin, Y., Kirkwood, J.M., Storkus, W.J., Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology, 3, 2014, e27589.
32. Nocera, N.F., Lee, M.C., La, Cruz LMD, Rosemblit, C., Czerniecki, B.J., Restoring lost anti-HER-2 Th1 immunity in breast cancer: a crucial role for Th1 cytokines in therapy and prevention. Front. Pharmacol. 7 (2016), 1–12.
33. Kohrt, H.E., Houot, R., Weiskopf, K., Goldstein, M.J., Scheeren, F., Czerwinski, D., Colevas, A.D., Weng, W.K., Clarke, M.F., Carlson, R.W., et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122 (2012), 1066–1075.
34. Datta, J., Rosemblit, C., Berk, E., Showalter, L., Namjoshi, P., Mick, R., Lee, K.P., Brod, A.M., Yang, R.L., Kelz, R.R., et al. Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology, 4, 2015, e1022301 This study shows that impaired Th1 immune response in HER2-driven breast cancer patients can be restored by specific DC vaccination that may improve immune response to neoadjuvant trastuzumab/chemotherapy.
35. Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., Kroemer, G., Cancer and the gut microbiota: An unexpected link. Sci. Transl. Med., 7, 2015 271ps1-271ps1.
36. Hu, S., Liu, L., Chang, E.B., Wang, J.Y., Raufman, J.P., Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol. Cancer, 14, 2015, 180.
37. Kostic, A.D., Gevers, D., Pedamallu, C.S., Michaud, M., Duke, F., Earl, A.M., Ojesina, A.I., Jung, J., Bass, A.J., Tabernero, J., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22 (2012), 292–298.
38. Agus, A., Denizot, J., Thévenot, J., Martinez-Medina, M., Massier, S., Sauvanet, P., Bernalier-Donadille, A., Denis, S., Hofman, P., Bonnet, R., et al. Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci. Rep., 6, 2016, 19032.
39. Velicer, C.M., Heckbert, S.R., Lampe, J.W., Potter, J.D., Robertson, C.A., Taplin, S.H., Antibiotic use in relation to the risk of breast cancer. JAMA 291 (2004), 827–835.
40. Rossini, A., Rumio, C., Sfondrini, L., Tagliabue, E., Morelli, D., Miceli, R., Mariani, L., Palazzo, M., Ménard, S., Balsari, A., Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. Cancer Res. 66 (2006), 6219–6224.
41. Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., Caviglia, J.M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
42. Iida, N., Dzutsev, A., Stewart, C.A., Smith, L., Bouladoux, N., Weingarten, R.A., Molina, D.A., Salcedo, R., Back, T., Cramer, S., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (80-.) 342 (2013), 967–970.
43. Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C.P.M., Flament, C., Lepage, P., Roberti, M.P., et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45 (2016), 931–943 This study highlights that the anticancer efficacy of cyclophosphamide requires immune contexture changes that depend on some commensals from the gut microbiota.
44. Hartstra, A.V., Bouter, K.E.C., Bäckhed, F., Nieuwdorp, M., Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38 (2015), 159–165.
45. Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R.S., Bartelsman, J.F.W.M., Dallinga-Thie, G.M., Ackermans, M.T., Serlie, M.J., Oozeer, R., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 2012, 143.
46. Louis, P., Hold, G.L., Flint, H.J., The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12 (2014), 661–672.
47. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F.L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13 (2016), 473–486.
48. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., Allison, J.P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206 (2009), 1717–1725.
49. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
50. Restifo, N.P., Smyth, M.J., Snyder, A., Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16 (2016), 121–126 Views of three scientists on evidence for the existence of acquired resistance to immunotherapy in patients and discussion of future issues related to immunotherapy.
51. Apetoh, L., Ladoire, S., Coukos, G., Ghiringhelli, F., Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Ann. Oncol. 26 (2015), 1813–1823.
52. Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44 (2016), 343–354 The authors show that chemotherapeutic agents by inducing tumor immunogenicity through the triggering of tumor T cell infiltration can sensitize unresponsive neoplasms to immune checkpoint blockers.
53. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
54. Mathios, D., Kim, J.E., Mangraviti, A., Phallen, J., Park, C., Jackson, C.M., Garzon-muvdi, T., Kim, E., Theodros, D., Polanczyk, M., et al. Anti – PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 8 (2016), 1–12 This study reveals that local delivery of chemotherapy can ameliorate the effects of immunotherapy, hence highlighting a novel aspect to consider for the optimization of chemo-immunotherapy combination.
55. Fridman, W.H., Pagès, F., Sautès-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.